Topic Podcasts - PsA Part1 Best of PsA on Day 1 #ACR22 https://t.co/uXxUwy6u9G https://t.co/GDDXgcn2EC

SLE, Sex and STDs Once in a while, I find an abstract at the American College of Rheumatology meeting that can potentially save lives and be implemented in practice now. Dr. Dao ( @KDAO2011) discusses abstract #0939 presented at #ACR22. https://t.co/0DtAgzB41G https://t.co/O1z7J0O4c6

TNFi cycling in axSpA: Results from CorEVITAS Registy study Dr. Rachel Tate ( @uptotate) reviews abstract #1499 presented at #ACR22. https://t.co/rvzB2RHkAD https://t.co/m3uiXAvZmZ

JAKi Regulatory Decisions - FDA, EMA, Canada New download available! https://t.co/92qbWQbMm3 https://t.co/lEjyjwxYMo

New Treatments for SLE? Dr. Petri discusses abstract 1117 presented at #ACR22. Efficacy & Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients w/Active SLE: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study https://t.co/nKOserLdbb https://t.co/xhVsxT8BZW

RA Topic Panel RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan https://t.co/GMqRmF2yXA https://t.co/WmYRTp49Rv

Proposed Cancer Screening for Inflammatory Myositis Patients 11/12's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. https://t.co/JlGGZ6UnOc https://t.co/86OnuLINPy

RheumNow Rheumatology Roundup Dr. Jack Cush and Dr. Arthur Kavanaugh discuss, dissect and deliberate the sessions and data presented at the #ACR22 meeting in Philadelphia. https://t.co/ppe5I5upvj https://t.co/su4SOS7MAg

Monday #ACR22 Daily Recap https://t.co/QZTag5Hyol https://t.co/rgpxI9AOHP

FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety data review reports of hypocalcemia w/ advanced CKD. Monitor Ca, use Ca & vit D supplements. Await further FDA information https://t.co/QMOtYs0eBY https://t.co/wzhIg53kCs

COVID Highlights Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at #ACR22 https://t.co/DEUykGt8pT https://t.co/sz8GRRGrPH

Do oral JAKs in atopic dermatitis cause VTE? Meta-analysis (15 RCTs, 466 993 pts) does NOT show increased risk of VTE associated with AD & JAK inhibitors (HR 0.95) w/ low VTE incidence (0.05%) w/ JAKi and (0.03%) placebo. https://t.co/mO2DHzjVJw https://t.co/aaC82UStob